Location [1]
Cell cycle control
Protein [2]
Cyclin-dependent kinase 4 inhibitor C
Synonyms [1]
p18, INK4C, p18-INK4C

Cyclin-dependent kinase inhibitor 2C (CDKN2C, also known as p18) is a gene that encodes a protein that inhibits the activation of CDK 4 and CDK6. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as bone cancer, endometrial cancer, and intestinal cancer.

CDKN2C is altered in 0.74% of all cancers with malignant glioma, non-small cell lung carcinoma, colorectal adenocarcinoma, sarcoma, and breast carcinoma having the greatest prevalence of alterations [3].

CDKN2C GENIE Cases - Top Diseases

The most common alterations in CDKN2C are CDKN2C Loss (0.22%), CDKN2C Amplification (0.11%), CDKN2C Deletion (0.01%), CDKN2C T88S (0.01%), and CDKN2C D17Gfs*7 (0.01%) [3].

CDKN2C GENIE Cases - Top Alterations

Significance of CDKN2C in Diseases

Glioblastoma +

Malignant Glioma +

Glioma +

Meningioma +

Multiple Myeloma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.